Esomeprazole Magnesium
Brand Names: Nexium, Acid Reducer, Nexium 24hr, Nexium 24hr Clearminis
Methodology & AI Transparency ⓘ
Esomeprazole Magnesium Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Esomeprazole magnesium is a proton pump inhibitor (PPI).
- 2 Real-world patient consensus: Zero-PHI community consensus: 92% favorable across 21 logged regimens (Nexium, Acid Reducer).
- 3 Typical cash cost range: Uninsured 30-day outlay compares $5.84 wholesale mail-order against $34.50 retail pharmacy pricing.
- 4 Top reported side effects / signs: Key post-marketing and trial adverse reactions (Esomeprazole Magnesium): nausea (11.1%), headache (9.7%), diarrhea (8.4%).
Ask our AI Specialists anything about Esomeprazole Magnesium
Esomeprazole Magnesium Mechanism, CYP450 Pathways & DailyMed Monograph
Esomeprazole magnesium is a proton pump inhibitor (PPI). Esomeprazole magnesium delayed-release capsules are indicated for the: Short-term treatment in the healing of erosive esophagitis (EE) in adults and pediatric patients 12 years to 17 years of age. ( 1.1 ) Maintenance of healing of EE in adults. ( 1.2 ) Short-term treatment of heartburn and other symptoms associated GERD in adults and pediatric patients 12 years to 17 years of age.
12.1 Mechanism of Action Esomeprazole belongs to a class of antisecretory compounds, the substituted benzimidazoles, that suppress gastric acid secretion by specific inhibition of the H+/K+ ATPase enzyme system at the secretory surface of the gastric parietal cell. Esomeprazole is protonated and converted in the acidic compartment of the parietal cell forming the active inhibitor, the achiral sulphenamide. Because this enzyme system is regarded as the acid (proton) pump within the gastric mucosa, esomeprazole has been characterized as a gastric acid-pump inhibitor, in that it blocks the final step of acid production.
Following administration (40 mg/1 Capsule, Delayed Release), Esomeprazole Magnesium achieves ~90% systemic bioavailability (Esomeprazole Magnesium) bioavailability and maximum serum exposure occurs 2–4 hours after esomeprazole magnesium dosing onset, governed by a Steady-state plasma equilibrium reached over 6–15 hour t½ intervals for Esomeprazole Magnesium terminal half-life through predominantly hepatic biotransformation with renal elimination of polar esomeprazole magnesium conjugates.
Before initiating Esomeprazole Magnesium at 40 mg/1 Capsule, Delayed Release, clinical safety checklists rule out esomeprazole magnesium is contraindicated in patients with known hypersensitivity to substituted benzimidazoles or to any component of the formulation.; hypersensitivity reactions may include anaphylaxis, anaphylactic shock, angioedema, bronchospasm, acute tubulointerstitial nephritis, and urticaria .. Logged tolerability patterns center on nausea (11.1% of reports), headache (9.7% of reports), diarrhea (8.4% of reports).
Reconcile eGFR-adjusted medications before escalating Esomeprazole Magnesium in polypharmacy regimens.
Unstandardized herbal extracts may interact pharmacodynamically with Esomeprazole Magnesium maintenance therapy.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Esomeprazole magnesium is contraindicated in patients with known hypersensitivity to substituted benzimidazoles or to any component of the formulation.
- Hypersensitivity reactions may include anaphylaxis, anaphylactic shock, angioedema, bronchospasm, acute tubulointerstitial nephritis, and urticaria .
Logged Side-Effect Incidence (21 Reports)
Esomeprazole Magnesium Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Esomeprazole Magnesium)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Vonoprazan-based quadruple therapy is non-inferior to esomeprazole-based: What a 510-Participant Study Found Vonoprazan was found to be well-tolerated and non-inferior to esomeprazole for eradicating H. Chinese medical journal • 2025-11-20 • Phase III Randomized Trial | N = 510 | 93/100 | PMID 39965795 ↗ |
| New Insights on Benefits and safety of tegoprazan (LXI-15028) vs . esomeprazole in patients with: What a 261-Participant Study Found Tegoprazan 50 mg/day demonstrated non-inferior efficacy in healing EE, symptom improvement, and quality of life, and it has similar tolerability compared with esomeprazole 40 mg/day. Chinese medical journal • 2025-10-05 • Phase III Randomized Trial | N = 261 | 93/100 | PMID 39474720 ↗ |
| New Insights on Randomized, gold-standard blind, Active-Controlled Phase 3 Study to Evaluate: What a 300-Participant Study Found In the full analysis set, the cumulative healing rate at week 8 were 97.92% (141/144) for zastaprazan and 94.93% (131/138) ( P = 0.178) for esomeprazole. The American journal of gastroenterology • 2025-02-01 • Phase III Randomized Trial | N = 300 | 93/100 | PMID 38976448 ↗ |
| Can This Approach Help? Inside the Latest Research on Proton pump inhibition for secondary hemochromatosis in hereditary anemia: a In summary, esomeprazole resulted in a significant reduction in liver iron content when compared to placebo in a heterogeneous group of patients with non-transfusion-dependent hereditary anemias. American journal of hematology • 2022-07-15 • Phase III Randomized Trial | N = 30 | 88/100 | PMID 35472008 ↗ |
Esomeprazole Magnesium Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.1397/unit (~$4.19/30u) | Wholesale baseline |
| Mark Cuban Cost Plus Drugs (Mail-Order Generic) | Public Wholesale Price List (NADAC + 15% + pharmacy fee) | $5.84 / mo | Formulary listing ↗ |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $34.50 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 21 Anonymous DotMD Community Micro-Logs | $7.50 / mo | View logs ↓ |
Esomeprazole Magnesium Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Esomeprazole Magnesium RxNorm Concept ID | 606726 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.1397 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $34.50 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $5.84 / mo (Cost Plus Drugs) | Mark Cuban Cost Plus Public API |
| Real-World Patient Consensus | 92.00% Worth It (21 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Esomeprazole Magnesium Patient Community, Cohort Filters & Dosage Logs
Deterministic Esomeprazole Magnesium reference combining NIH RxNorm (606726), Medicaid NADAC ($0.1397/unit), and anonymous cohort outcomes (92% Worth It).
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Esomeprazole Magnesium community threads and patient logs by age, biological sex, dosage, and treatment duration.